22 COVID-19 vaccines enter clinical trials in China: health official
Xinhua |
Updated: 2021-07-08 19:36
Share
Share - WeChat
BEIJING - Twenty-two COVID-19 vaccines have been approved to enter clinical trials in China, a health official said Thursday.
To date, four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for emergency use within the country, said Yuan Lin, an official with the National Medical Products Administration (NMPA), at a press conference in Beijing.
By the end of June, the NMPA had granted emergency approval for clinical trials to 25 drugs intended for the treatment of COVID-19 and its indications, Yuan added.
- Senior Xi'an official facing probe by China's anti-corruption watchdogs
- Philippines risks creating trouble for itself: China's defense ministry
- Newborn with congenital heart disease receives life-saving surgery in Yunnan
- Hong Kong charity signs diplomatic talent deal with Beijing university
- Aircraft carrier Fujian, commissioned
- Erdos offers 10,000 yuan subsidy for families having third child
